Samsung Bioepis: Final European Approval for Remicade CopySamsung Bioepis: Final European Approval for Remicade Copy

South Korea's Samsung Bioepis said on Monday its biosimilar of Johnson & Johnson's blockbuster rheumatoid arthritis drug Remicade (infliximab) has received final approval from European regulators, paving the way for its second product launch in Europe. International Approvals
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news